ValiRx plc (GB:VAL) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
ValiRx Plc, through its subsidiary Inaphaea BioLabs, has partnered with Italian biobanking service provider BioRep to enhance the distribution of its drug screening services and Patient Derived Cells in Europe. The collaboration will leverage BioRep’s logistics, sample management, and molecular biology services to expand ValiRx’s reach. The agreement includes co-marketing initiatives and royalty sharing on contracts, aiming to facilitate oncology research and sample provision in the European market.
For further insights into GB:VAL stock, check out TipRanks’ Stock Analysis page.
